サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ファブリー病治療市場- 成長、将来展望、競合分析、2023～2031年
市場調査レポート
商品コード
1313690

ファブリー病治療市場- 成長、将来展望、競合分析、2023～2031年

Fabry Disease Therapeutic Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 112 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
ファブリー病治療市場- 成長、将来展望、競合分析、2023～2031年
出版日: 2023年06月08日
発行: Acute Market Reports
ページ情報: 英文 112 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファブリー病治療市場は2031年までに6.5％の成長が見込まれるファブリー病は、α-ガラクトシダーゼAという酵素の活性欠損に起因する、X連鎖性のまれな遺伝性脂質代謝異常症です。この酵素は通常グロボトリアオシルセラミドの分解を担うが、その結果、全身の血管壁に特定の脂肪物質が異常に沈着します。ファブリー病の特徴的な症状としては、疼痛、眼の前面の混濁、皮膚に小さな暗赤色の斑点、難聴、心臓発作、腎臓障害、脳卒中などの生命を脅かす合併症が挙げられます。ファブリー病は、古典的表現型の1型と遅発性表現型の2型に分けられます。NORD（National Organization for Rare Disorder）によると、1型古典的表現型の発症率は男性で約40,000人に1人であるが、人口構成や人種によって異なり、約18,000人に1人から95,000人に1人です。男性における2型後発症の発症率は、民族、人口統計学、人種によって異なるが、同じ地域、民族、人種の1型古典的表現型の発症率の少なくとも10倍です。

ファブリー病の治療法はないが、治療薬はあります。治療には酵素補充療法（ERT）が用いられます。現在市販されているERT製剤は、リプレガルとファブラザイムの2種類のみで、これらは点滴静注により投与されます。米国ではサノフィ・ジェンザイム社のアガルシダーゼ・ベータ（ファブラザイム）のみがFDA承認を受けています。Shire社のアガルシダーゼ・アルファ（Replagal）は欧州をはじめ多くの国で承認されているが、米国では承認されていないです。ファブラザイムとリプレガルは2週間ごとに投与され、生涯、または他の適切な薬剤が使用可能になるまで投与されます。ERTは非常に高価な治療法です。その他の治療には、疼痛治療薬、胃の亢進を治療する薬、血液希釈薬、不整脈やその他の心臓疾患を管理する薬など、症状を軽減するための薬物療法も含まれます。

世界のファブリー病治療市場の主な促進要因としては、研究開発における広範な調査と先端技術の採用が挙げられます。SMP-536、PRX-102、AT-1001、GC-1119、SAR-402671、PRX-102など様々な治療薬が臨床試験中です。ファブリー病は、政府および民間保険によってICD-10-CMコードに指定されており、償還目的の診断を示すために使用することができます。世界のファブリー病市場成長の主な障壁は、この疾患のまれな発生率（40,000分の1）です。

Genzyme-Sanofi社やShire社などの企業が市場の主要プレーヤーです。新薬開発に携わる主な企業には、アミカス・セラピューティクス、シャイアー、ジェンザイム・サノフィ、プロタリックス、サノフィ・アベンティスLLC、ノバルティス・ファーマシューティカルズ、ファイザー、ブリストル・マイヤーズスクイブ、グラクソ・スミスクライン、アムジェン、テバ・ファーマシューティカル・インダストリーズ、メルク・アンド・カンパニー、アッヴィ、武田薬品工業、グリーンクロス、武田薬品工業などがあります。武田薬品工業株式会社その他の主要企業。

本レポートは以下を提供します：

  • ファブリー病治療の世界市場の概要
  • 2014年から2024年までの市場動向評価（2014年と2015年の過去情報、2024年までの予測、2016年から2024年の各CAGR付き）
  • 市場促進要因・課題・将来展望などの定性的評価ツール。
  • 市場シェア分析、フラクタルマップ評価などの市場競争精査ツール
  • 製品の承認、上市、現在および予測される市場力学に基づく各レベルの市場セグメンテーションにフォーカス
  • 業界構造の概要
  • ファブリー病治療市場で事業展開する主要企業に関する主要情報を強調した企業プロファイル

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 ファブリー病治療市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs 2031

第4章 ファブリー病治療市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のファブリー病治療市場金額 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 ファブリー病治療市場：薬剤の種類別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 酵素補充療法
    • 代替療法

第6章 北米のファブリー病治療市場 2021-2031

  • 市場概要
  • ファブリー病治療市場：薬剤の種類別 2021-2031
  • ファブリー病治療市場：地域別 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第7章 英国と欧州連合のファブリー病治療市場 2021-2031

  • 市場概要
  • ファブリー病治療市場：薬剤の種類別 2021-2031
  • ファブリー病治療市場：地域別 2021-2031
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第8章 アジア太平洋のファブリー病治療市場 2021-2031

  • 市場概要
  • ファブリー病治療市場：薬剤の種類別 2021-2031
  • ファブリー病治療市場：地域別 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第9章 ラテンアメリカのファブリー病治療市場 2021-2031

  • 市場概要
  • ファブリー病治療市場：薬剤の種類別 2021-2031
  • ファブリー病治療市場：地域別 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第10章 中東・アフリカのファブリー病治療市場 2021-2031

  • 市場概要
  • ファブリー病治療市場：薬剤の種類別 2021-2031
  • ファブリー病治療市場：地域別 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第11章 企業プロファイル

  • Amicus therapeutics
  • Shire
  • Genzyme-Sanofi
  • Protalix
  • Sanofi-Aventis LLC
  • Novartis Pharmaceuticals
  • Pfizer
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Teva pharmaceutical Industries Ltd.
  • Merck & Co.
  • AbbVie Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Green Cross Corp.
  • その他の主要企業
図表

List of Tables

  • TABLE 1 Global Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 2 North America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 3 U.S. Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 4 Canada Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 5 Rest of North America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 6 UK and European Union Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 7 UK Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 8 Germany Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 9 Spain Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 10 Italy Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 11 France Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 12 Rest of Europe Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 13 Asia Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 14 China Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 15 Japan Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 16 India Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 17 Australia Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 18 South Korea Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 19 Latin America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 20 Brazil Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 21 Mexico Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 22 Rest of Latin America Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 23 Middle East and Africa Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 24 GCC Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 25 Africa Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Fabry Disease Therapeutic Market By Drug Type, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Fabry Disease Therapeutic Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Fabry Disease Therapeutic Market: Quality Assurance
  • FIG. 5 Global Fabry Disease Therapeutic Market, By Drug Type, 2022
  • FIG. 6 Global Fabry Disease Therapeutic Market, By Geography, 2022
  • FIG. 7 Market Geographical Opportunity Matrix - Global Fabry Disease Therapeutic Market, 2022

FIG. 8Market Positioning of Key Fabry Disease Therapeutic Market Players, 2022

FIG. 9Global Fabry Disease Therapeutic Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 10 Global Fabry Disease Therapeutic Market, By Drug Type, 2022 Vs 2031, %
  • FIG. 11 U.S. Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 12 Canada Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 13 Rest of North America Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 14 UK Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 15 Germany Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 16 Spain Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 17 Italy Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 18 France Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of Europe Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 20 China Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 21 Japan Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 22 India Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 23 Australia Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 24 South Korea Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Asia Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 26 Brazil Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 27 Mexico Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 28 Rest of Latin America Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 29 GCC Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 30 Africa Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Middle East and Africa Fabry Disease Therapeutic Market (US$ Million), 2021 - 2031
目次
Product Code: 137335-06-23

Fabry disease therapeutic market expected to Grow at 6.5% by 2031, Fabry disease is a rare, X-linked inherited, disorder of lipid metabolism resulting from the deficient activity of the enzyme, alpha-galactosidase-A. This enzyme normally responsible for the breakdown of globotriaosylceramide, results in abnormal deposits of a particular fatty substance in walls of the blood vessel throughout the body. Characteristic features of Fabry disease include episodes of pain, cloudiness of the front part of the eye, clusters of small and dark red spots on the skin, hearing loss also involves life-threatening complications such as heart attack, kidney damage and stroke. Fabry disease can be divided into two types, type 1 classic phenotype and type 2 later-onset phenotype. According to National Organization for Rare Disorder (NORD) the incidence of type 1 classic phenotype is about 1 in 40,000 in males, but varies with demography and race, ranging from about 1 in 18,000 to 1 in 95,000. The incidence of type 2 later-onset in males varies by ethnicity, demography and race, but is at least 10 times more frequent than that of the type 1 classic phenotype from the same region, ethnic group or race.

There is no cure for Fabry disease, but medications are available treat the condition. Enzyme Replacement Therapy (ERT) is used for treatment. Currently only two ERT preparations such as Replagal and Fabrazyme are available in the market that are administered by intravenous infusion. In the USA, only Sanofi-Genzyme's agalsidase beta (Fabrazyme) is FDA approved. Shire's Agalsidase alfa (Replagal) is approved in Europe and many other countries but not in the United States. Fabrazyme and Replagal is administered after every two weeks for lifetime or until another appropriate medication becomes available. ERT is extremely expensive treatment. Other treatment may also involve medications to reduce symptoms such as pain medications, medications to treat stomach hyperactivity, blood thinners and medication to manage arrhythmias and other heart disorders.

Key drivers for the global fabry disease therapeutic market includes, extensive investigations and adoption of advance technology in research and development. Various therapeutic products, such as, SMP-536, PRX-102, AT-1001, GC-1119, SAR-402671, PRX-102 and other are in clinical trial studies. Fabry disease has been designated ICD-10-CM code by government and private insurance that can be used to indicate diagnosis for reimbursement purpose, which would further drive the market. Major barriers of growth for the global for Fabry disease market is rare incidence rate of the disorder (1:40,000).

Companies such as Genzyme-Sanofi and Shire are the major player in market as only these company have approved drugs in the market currently. Major players involved in development of new medications include Amicus therapeutics, Shire, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva pharmaceutical Industries Ltd., Merck & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., Green Cross Corp. And Other Notable Players.

This report offers:

  • An overview of the global markets for Fabry Disease Therapeutics
  • Market trends assessment for the period 2014-2024, with historical information for 2014 & 2015, and projections through 2024, with respective CAGRS during 2016-2024
  • Qualitative assessment tools such as market drivers, challenges and future prospects.
  • Market competition scrutiny tools such as market share analysis, fractal map assessment.
  • Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
  • A general overview of the industry structure
  • Company profiles highlighting key information about the major players operating in the Fabry Disease Therapeutics Market

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofFabry Disease Therapeutic market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Fabry Disease Therapeutic market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

  • Enzyme Replacement Therapy
  • Alternative therapies

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Fabry Disease Therapeutic market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Fabry Disease Therapeutic market?
  • Which is the largest regional market for Fabry Disease Therapeutic market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Fabry Disease Therapeutic market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Fabry Disease Therapeutic market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Fabry Disease Therapeutic Market
  • 2.2. Global Fabry Disease Therapeutic Market, By Drug Type, 2022 (US$ Million)
  • 2.3. Global Fabry Disease Therapeutic Market, By Geography, 2022 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2022

3. Fabry Disease Therapeutic Market: Competitive Analysis

  • 3.1. Market Positioning of Key Fabry Disease Therapeutic Market Vendors
  • 3.2. Strategies Adopted by Fabry Disease Therapeutic Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Fabry Disease Therapeutic Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Fabry Disease Therapeutic Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Enzyme Replacement Therapy
    • 5.3.2. Alternative therapies

6. North America Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 6.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

7. UK and European Union Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 7.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

8. Asia Pacific Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 8.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

9. Latin America Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 9.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

10. Middle East and Africa Fabry Disease Therapeutic Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
  • 10.3.Fabry Disease Therapeutic Market: By Region, 2021-2031, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Fabry Disease Therapeutic Market: By Drug Type, 2021-2031, USD (Million)

11. Company Profile

  • 11.1. Amicus therapeutics
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Shire
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Genzyme-Sanofi
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Protalix
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Sanofi-Aventis LLC
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Novartis Pharmaceuticals
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Pfizer
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Bristol-Myers Squibb Company
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. GlaxoSmithKline plc
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Amgen Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Teva pharmaceutical Industries Ltd.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Merck & Co.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. AbbVie Inc.
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Takeda Pharmaceutical Co. Ltd.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives
  • 11.15. Green Cross Corp.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Portfolio
    • 11.15.4. Strategic Initiatives
  • 11.16. Other Notable Players
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Portfolio
    • 11.16.4. Strategic Initiatives